TG Therapeutics (NASDAQ:TGTX) Rating Reiterated by HC Wainwright

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $49.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 93.83% from the company’s current price.

TGTX has been the subject of a number of other reports. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. B. Riley raised their price objective on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.83.

TG Therapeutics Price Performance

NASDAQ TGTX opened at $25.28 on Wednesday. The company’s 50 day simple moving average is $21.93 and its 200 day simple moving average is $18.25. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The firm has a market capitalization of $3.91 billion, a PE ratio of 109.91 and a beta of 2.21. TG Therapeutics has a 12 month low of $6.46 and a 12 month high of $26.41.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The firm had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. During the same period in the previous year, the company earned ($0.34) earnings per share. TG Therapeutics’s revenue was up 357.0% compared to the same quarter last year. As a group, equities research analysts forecast that TG Therapeutics will post 0.13 EPS for the current fiscal year.

Institutional Trading of TG Therapeutics

Hedge funds have recently modified their holdings of the business. Pingora Partners LLC acquired a new position in TG Therapeutics during the fourth quarter valued at $27,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of TG Therapeutics in the 2nd quarter valued at about $35,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of TG Therapeutics in the first quarter worth approximately $58,000. nVerses Capital LLC boosted its holdings in shares of TG Therapeutics by 34.9% during the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 1,500 shares during the period. Finally, Quarry LP grew its position in TG Therapeutics by 9.1% during the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 503 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.